Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Allergan USA, Inc. v. Imprimis Pharmaceuticals, Inc.
Case Number:
8:17-cv-01551
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
November 27, 2017
'Seminal' Allergan Cases Test Copycat Drug Limits
Two recently filed lawsuits from Allergan PLC are teeing up a pivotal test of the extent to which drug compounders can mass-produce virtual copies of brand-name prescription drugs, attorneys say.
-
November 15, 2017
Eye-Drug Compounder Can't Dodge Allergan Suit
A California federal judge on Tuesday kept alive Allergan's false advertising suit against a large drug compounder, saying there are sufficient allegations the compounder is manufacturing eye medicines without adhering to federal law.
-
October 25, 2017
Compounder Can't Duck Drug Marketing Suit, Allergan Says
Allergan has asked a California federal judge not to toss its suit alleging Imprimis Pharmaceuticals illegally manufactures and sells unapproved new drugs under a drug compounding loophole in FDA regulations, saying it has shown that it complies with the Federal Food, Drug and Cosmetics Act and state regulations.
- ← Previous
- 1
- 2
- Next →